These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30049825)

  • 1. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
    Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M;
    Haematologica; 2018 Sep; 103(9):1422-1432. PubMed ID: 30049825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
    Breccia M; Carver JR; Szmit S; Jurczak W; Salvatorelli E; Minotti G
    Semin Oncol; 2019 Dec; 46(6):403-407. PubMed ID: 31748121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cardiovascular risk in patients with multiple myeloma.
    Plummer C; Driessen C; Szabo Z; Mateos MV
    Blood Cancer J; 2019 Feb; 9(3):26. PubMed ID: 30808934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
    Heitner SB; Minnier J; Naher A; Van Woerkom RC; Ritts A; Ferencik M; Broberg C; Medvedova E; Silbermann R; Scott EC
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):796-802. PubMed ID: 30217616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
    Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
    Jakubowiak AJ; DeCara JM; Mezzi K
    Hematology; 2017 Dec; 22(10):585-591. PubMed ID: 28545322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies.
    El-Cheikh J; Moukalled N; Malard F; Bazarbachi A; Mohty M
    Blood Cancer J; 2023 May; 13(1):83. PubMed ID: 37208317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
    Chen Y; Lairson DR; Chan W; Du XL
    Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second primary malignancies in multiple myeloma: A review.
    Poh C; Keegan T; Rosenberg AS
    Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances.
    Camilli M; La Vecchia G; Lillo R; Iannaccone G; Lamendola P; Montone RA; Hohaus S; Aspromonte N; Massetti M; Lanza GA; Crea F; Graziani F; Lombardo A
    Expert Rev Hematol; 2021 Dec; 14(12):1115-1128. PubMed ID: 34739762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
    Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-oncological management of patients.
    Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
    Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
    Ludwig H; Delforge M; Facon T; Einsele H; Gay F; Moreau P; Avet-Loiseau H; Boccadoro M; Hajek R; Mohty M; Cavo M; Dimopoulos MA; San-Miguel JF; Terpos E; Zweegman S; Garderet L; Mateos MV; Cook G; Leleu X; Goldschmidt H; Jackson G; Kaiser M; Weisel K; van de Donk NWCJ; Waage A; Beksac M; Mellqvist UH; Engelhardt M; Caers J; Driessen C; Bladé J; Sonneveld P
    Leukemia; 2018 Jul; 32(7):1542-1560. PubMed ID: 29720735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 20. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
    Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
    Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.